Equities analysts expect AstraZeneca plc (NYSE:AZN) to post $0.44 earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for AstraZeneca’s earnings, with the highest EPS estimate coming in at $0.46 and the lowest estimate coming in at $0.42. AstraZeneca reported earnings of $1.12 per share during the same quarter last year, which suggests a negative year over year growth rate of 60.7%. The business is expected to report its next quarterly earnings report before the market opens on Thursday, November 8th.

On average, analysts expect that AstraZeneca will report full-year earnings of $1.68 per share for the current year, with EPS estimates ranging from $1.65 to $1.70. For the next fiscal year, analysts forecast that the firm will post earnings of $1.89 per share, with EPS estimates ranging from $1.85 to $1.93. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow AstraZeneca.

AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Thursday, July 26th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.38. The firm had revenue of $5.16 billion during the quarter, compared to analyst estimates of $5.09 billion. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.87 earnings per share.

A number of equities analysts have recently weighed in on the company. ValuEngine raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, July 28th. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, July 16th. BMO Capital Markets reaffirmed a “buy” rating and issued a $41.00 price objective on shares of AstraZeneca in a research note on Friday, May 25th. Morningstar reaffirmed a “hold” rating on shares of AstraZeneca in a research note on Tuesday, June 12th. Finally, Jefferies Financial Group downgraded AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Seven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $38.94.

Large investors have recently bought and sold shares of the stock. Bessemer Group Inc. lifted its position in shares of AstraZeneca by 64.3% in the second quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock worth $163,000 after buying an additional 1,820 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in AstraZeneca during the second quarter valued at approximately $175,000. Tiverton Asset Management LLC purchased a new stake in AstraZeneca during the second quarter valued at approximately $178,000. Gilman Hill Asset Management LLC purchased a new stake in AstraZeneca during the second quarter valued at approximately $205,000. Finally, Independent Advisor Alliance purchased a new stake in AstraZeneca during the second quarter valued at approximately $206,000. Institutional investors own 15.98% of the company’s stock.

Shares of NYSE AZN traded up $0.11 during mid-day trading on Friday, reaching $37.18. The company’s stock had a trading volume of 2,167,175 shares, compared to its average volume of 3,887,245. The firm has a market cap of $93.89 billion, a price-to-earnings ratio of 8.69, a price-to-earnings-growth ratio of 2.00 and a beta of 0.60. The company has a quick ratio of 0.54, a current ratio of 0.72 and a debt-to-equity ratio of 1.08. AstraZeneca has a 52 week low of $31.71 and a 52 week high of $39.76.

The company also recently announced a semiannual dividend, which will be paid on Monday, September 10th. Investors of record on Friday, August 10th will be given a $0.45 dividend. The ex-dividend date is Thursday, August 9th. This represents a dividend yield of 2.35%. AstraZeneca’s dividend payout ratio is currently 20.56%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: NASDAQ Stock Market Explained

Get a free copy of the Zacks research report on AstraZeneca (AZN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.